secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001367644-24-000142
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q2 revenue $254.7M, net loss $283.1M; updates FY2024 guidance
--------------------------------------------------------------------------------

- Q2 revenue $254.7M (above guidance); net loss $283.1M ($5.38/diluted), adjusted EBITDA -$10.1M.
- Bioservices services revenue $64.5M (+144% YoY) including $50M Janssen arbitration settlement; cost $211.6M with asset write-down.
- Updated FY2024: total revenue $1,050-$1,125M (raised); net loss $(314)-$(274)M (wider); adj. EBITDA $140-$180M (raised).
- Asset sales: $30M Baltimore-Camden site sale expected Q3 2024; $75M from RSDL sale to SERB; $50M Janssen dispute resolution.
- Impairment $27.2M in Q2 vs $306.7M a year ago, related to Bayview and Rockville asset groups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000142/0001367644-24-000142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000142/ebs-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer